Apparent Non-Response to Phosphodiesterase Type 5 Inhibitors in Erectile Dysfunction: A Narrative Review of Structured Reassessment and Management
Abstract
Background and Objectives: Apparent non-response to phosphodiesterase type 5 (PDE5) inhibitors is common, but the label conflates inadequate instruction or drug exposure, partial or absent response, treatment discontinuation, and coexisting clinical contributors. This narrative review presents an author-proposed structured reassessment framework, not a new or validated diagnostic classification. Materials and Methods: PubMed/MEDLINE was searched from database inception to 7 August 2026 using a documented, reproducible search strategy, with targeted checks of guideline, regulatory, clinical, observational, and mechanistic sources; selection was purposive, without a registered protocol, quantitative synthesis, or certainty-of-evidence grading. Results: PDE5 inhibitors preserve nitric oxide-cyclic guanosine monophosphate signaling but require sexual stimulation, adequate exposure, and sufficient erectile physiology. In one specialist-referral cohort, 88 of 250 men (35.2%) responded after structured re-education, being 88 of the 115 (76.5%) who accepted it, which should not be generalized. The framework separates trial and exposure adequacy, observed response documented with validated measures where feasible, targeted evaluation of contributing domains, and shared selection of oral optimization or an established non-oral option. Persistent clinically meaningful oral-PDE5-inhibitor non-response is defined by principle rather than by a fixed number of attempts, agents, or…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.